NCT05248763

Brief Summary

The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,190

participants targeted

Target at P75+ for all trials

Timeline
118mo left

Started Feb 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Feb 2022Dec 2035

First Submitted

Initial submission to the registry

January 24, 2022

Completed
28 days until next milestone

First Posted

Study publicly available on registry

February 21, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

February 21, 2022

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2035

Last Updated

July 20, 2022

Status Verified

July 1, 2022

Enrollment Period

4.9 years

First QC Date

January 24, 2022

Last Update Submit

July 18, 2022

Conditions

Malignant Neoplasm of Body of Stomach in Situ

Keywords

lung cancerbreast cancergastric cancerpancreatic cancerovarian cancer

Outcome Measures

Primary Outcomes (1)

  • Collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data

    Analyze collected clinical samples by using integrated proteomics and genetics platform (genome, transcriptome, genomic methylation, proteomics, and post-translational modification)

    Through study completion, an average of 2 to 3 year

Secondary Outcomes (1)

  • Differential expressed genes and proteins in tumor

    Through study completion, an average of 4 year

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer in Taiwan

You may qualify if:

  • lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer

You may not qualify if:

  • other cancer types

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, 100225, Taiwan

RECRUITING

MeSH Terms

Conditions

Lung NeoplasmsBreast NeoplasmsStomach NeoplasmsPancreatic NeoplasmsOvarian Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach DiseasesEndocrine Gland NeoplasmsPancreatic DiseasesEndocrine System DiseasesOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesGonadal Disorders

Study Officials

  • Yu-Ju Chen, PhD

    Distinguished Research Fellow

    STUDY DIRECTOR

Central Study Contacts

Yu-Ju Chen, PhD

CONTACT

886-2-55728660yujuchen@gate.sinica.edu.tw

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
4 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 24, 2022

First Posted

February 21, 2022

Study Start

February 21, 2022

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2035

Last Updated

July 20, 2022

Record last verified: 2022-07

Locations

TW(1)